100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.
复制标题
DOI:
10.1093/immadv/ltab024
复制
发表时间:
2021-01
影响因子:
--
通讯作者:
Walker LSK
中科院分区:
文献类型:
--
作者:
Pearson JA;McKinney EF;Walker LSK
Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here, we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.
登录
查看更多内容
影响因子:
7.7
作者:
CHRISTIANSON, SW;SHULTZ, LD;LEITER, EH
通讯作者:
LEITER, EH
影响因子:
7.7
作者:
Arif S;Leete P;Nguyen V;Marks K;Nor NM;Estorninho M;Kronenberg-Versteeg D;Bingley PJ;Todd JA;Guy C;Dunger DB;Powrie J;Willcox A;Foulis AK;Richardson SJ;de Rinaldis E;Morgan NG;Lorenc A;Peakman M
通讯作者:
Peakman M
影响因子:
4.3
作者:
Dolpady J;Sorini C;Di Pietro C;Cosorich I;Ferrarese R;Saita D;Clementi M;Canducci F;Falcone M
通讯作者:
Falcone M
影响因子:
3.7
作者:
de Groot PF;Belzer C;Aydin Ö;Levin E;Levels JH;Aalvink S;Boot F;Holleman F;van Raalte DH;Scheithauer TP;Simsek S;Schaap FG;Olde Damink SWM;Roep BO;Hoekstra JB;de Vos WM;Nieuwdorp M
通讯作者:
Nieuwdorp M
影响因子:
82.9
作者:
Belghith, M;Bluestone, JA;Chatenoud, L
通讯作者:
Chatenoud, L